Pharmacokinetic Effects of Antidrug Antibodies Occurring in Healthy Subjects After a Single Dose of Intravenous Infliximab

BACKGROUND: Infliximab pharmacokinetic studies have been performed in patients receiving chronic infliximab therapy. In these patients, infliximab antidrug antibodies (ADAs) increase infliximab clearance and decrease serum levels and drug efficacy. OBJECTIVE: This study analyzed the pharmacokinetic...

Descripción completa

Detalles Bibliográficos
Autor principal: Ehrenpreis, Eli D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2017
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5694424/
https://www.ncbi.nlm.nih.gov/pubmed/28879645
http://dx.doi.org/10.1007/s40268-017-0211-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5694424/
https://www.ncbi.nlm.nih.gov/pubmed/28879645
http://dx.doi.org/10.1007/s40268-017-0211-y

Ejemplares similares